Stockscreener 앱 받기
1.71%
전일 마감가:
$237.28
열려 있는:
$237.11
하루 거래량:
197.73K
Relative Volume:
0.24
시가총액:
$14.99B
수익:
$13.84B
순이익/손실:
$1.10B
주가수익비율:
22.42
EPS:
10.4185
순현금흐름:
$1.49B
1주 성능:
+0.70%
1개월 성능:
+11.23%
6개월 성능:
+113.63%
1년 성능:
+59.69%
1일 변동 폭
$231.84
$237.11
1주일 범위
$231.72
$238.64
52주 변동 폭
$101.00
$239.64
다비타 Stock (DVA) Company Profile
명칭
Davita Inc
전화
310-536-2668
주소
2000 16TH STREET, DENVER, CO
Compare DVA vs HCA, THC, FMS, EHC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
233.56 | 15.03B | 13.84B | 1.10B | 1.49B | 10.42 |
HCA
Hca Healthcare Inc
|
373.31 | 82.17B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
197.60 | 16.74B | 21.46B | 2.65B | 3.35B | 19.23 |
FMS
Fresenius Medical Care Ag Adr
|
24.41 | 12.93B | 22.44B | 1.35B | 2.03B | 1.9002 |
EHC
Encompass Health Corp
|
111.24 | 11.16B | 6.07B | 793.80M | 464.40M | 5.9914 |
다비타 Stock (DVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-06 | 개시 | Barclays | Equal Weight |
| 2023-08-07 | 업그레이드 | UBS | Neutral → Buy |
| 2022-11-01 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-10-31 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-08-19 | 재개 | UBS | Buy |
| 2022-06-21 | 재확인 | BofA Securities | Underperform |
| 2021-09-10 | 개시 | Cowen | Market Perform |
| 2021-08-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-03-26 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-10-25 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2019-09-11 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-01-08 | 업그레이드 | UBS | Sell → Neutral |
| 2019-01-03 | 개시 | Deutsche Bank | Buy |
| 2018-12-14 | 개시 | Barclays | Overweight |
| 2018-11-28 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-11-16 | 개시 | UBS | Sell |
| 2018-11-08 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2018-09-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-01-04 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-12 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2017-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2017-12-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2017-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-12-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
다비타 주식(DVA)의 최신 뉴스
DaVita stock holds on dialysis revenue and margin trends - Ad-hoc-news.de
DaVita Inc. to announce Q2FY26 results on August 4 - scanx.trade
DaVita schedules Q2 earnings call for August 4, 2026, after market close. - Pluang
DaVita Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call - Arizona Daily Star
What you need to know ahead of DaVita’s earnings release - MSN
DaVita stock trades steady as dialysis operator highlights cash flow and growth investments - Ad-hoc-news.de
DaVita stock holds firm as earnings and cash flow support dialysis strategy - Ad-hoc-news.de
DaVita stock benefits from expanding community-based kidney care - MSN
DaVita stock trades steadily as dialysis margins and leverage stay in focus - Ad-hoc-news.de
DaVita stock trades steady as chronic kidney care demand supports earnings trajectory - ad-hoc-news.de
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors - Yahoo Finance
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
DaVita Wins Bid To Decertify 1,300-Member Collective - Law360
DaVita: Why We Exited Our Position In Q2 (DVA) - Seeking Alpha
DaVita gains 21.4% in three months: How should you play the stock? - MSN
DaVita stock trades steadily as kidney care margins and cash flow support valuation - Ad-hoc-news.de
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
DaVita Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DaVita shares more than double after strong Q1 and court win; analyst sells most shares, rates Hold. - Pluang
DaVita: I Believe This Is Overvalued (NYSE:DVA) - Seeking Alpha
What You Need To Know Ahead of DaVita’s Earnings Release - Yahoo Finance
DaVita Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Truist Raises Price Target on DaVita to $250 From $205, Keeps Hold Rating - Moomoo
Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $250 - Moomoo
DaVita expands comprehensive kidney care through dialysis services - MSN
DaVita Company Profile & Introduction - Moomoo
DaVita stock holds steady as kidney care specialist focuses on operations and long-term dialysis dem - ad-hoc-news.de
DaVita Inc. (DVA) Stock Analysis: Strong ROE And Growth Potential In Healthcare Sector - DirectorsTalk Interviews
Exciting News for Farmington: DaVita Maple Valley is Expandi... - Park Hills Daily Journal
DaVita stock reflects steady dialysis demand amid US healthcare focus - ad-hoc-news.de
DVA stock holds steady as dialysis demand underpins the long-term case - ad-hoc-news.de
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why - Yahoo Finance
DaVita Can Return to Long-Term Volume Growth of 2% by 2029, UBS Says - Moomoo
DaVita stock holds steady as kidney care demand supports long term outlook - ad-hoc-news.de
UBS Adjusts Price Target on DaVita to $270 From $235 - marketscreener.com
Everyone Is Watching Greg Abel. But Another Berkshire Hathaway Stock Picker Is Quietly Winning in 2026. - The Motley Fool
DAVITA INC. : BARCLAYS RAISES TARGET PRICE TO $218 FROM $194 - Moomoo
DaVita Inc focus on kidney care operations as investors watch US healthcare demand - Ad-hoc-news.de
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
DaVita stock benefits from strengthening kidney care delivery - MSN
DaVita Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DaVita Inc. focuses on core dialysis services as investors watch U.S. healthcare trends - ad-hoc-news.de
Barclays Adjusts Price Target on DaVita to $218 From $194 - Moomoo
DaVita (DVA) Q2 2024 earnings summary - Quartr
The DaVita In-Center HemodialysisA core service tailored to U.S. kidney patients - ad-hoc-news.de
DaVita Stock On Fire: Up 13% With 10-Day Winning Streak - Trefis
DaVita Inc. on Track for Record High Close -- Data Talk - Moomoo
DaVita Stock Rockets 13% With 10-Day Winning Streak - Trefis
DaVita Inc. outlines growth path as kidney care demand rises - AD HOC NEWS
DaVita Inc and its role in the US dialysis market. Long-term fundamentals and business model in focu - AD HOC NEWS
다비타 (DVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
0.37%
자본화:
|
볼륨(24시간):